Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $29.89 Average Price Target from Brokerages

Posted by Brian Himes on May 19th, 2026

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $29.6316.

A number of research analysts have recently issued reports on the company. Benchmark assumed coverage on Tandem Diabetes Care in a research note on Monday, May 11th. They set a “hold” rating on the stock. Mizuho set a $24.00 price objective on Tandem Diabetes Care in a research note on Friday, May 8th. Piper Sandler raised Tandem Diabetes Care from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $33.00 in a research note on Tuesday, March 17th. Morgan Stanley raised their price objective on Tandem Diabetes Care from $23.00 to $25.00 and gave the company an “equal weight” rating in a research note on Monday, March 2nd. Finally, Barclays set a $55.00 price objective on Tandem Diabetes Care and gave the company an “overweight” rating in a research note on Monday, May 11th.

Read Our Latest Analysis on TNDM

Institutional Trading of Tandem Diabetes Care

Large investors have recently modified their holdings of the business. Sector Gamma AS lifted its stake in Tandem Diabetes Care by 28.0% in the third quarter. Sector Gamma AS now owns 269,542 shares of the medical device company’s stock worth $3,272,000 after acquiring an additional 59,019 shares during the period. Counterpoint Mutual Funds LLC purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at $513,000. Royce & Associates LP bought a new position in Tandem Diabetes Care in the 3rd quarter worth $6,191,000. Vanguard Group Inc. raised its holdings in Tandem Diabetes Care by 3.9% in the 4th quarter. Vanguard Group Inc. now owns 7,341,356 shares of the medical device company’s stock worth $161,363,000 after purchasing an additional 278,042 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter worth about $26,988,000.

Tandem Diabetes Care Stock Up 5.5%

Shares of NASDAQ:TNDM opened at $13.53 on Friday. The stock’s 50-day moving average price is $19.87 and its 200-day moving average price is $20.29. Tandem Diabetes Care has a 12-month low of $9.98 and a 12-month high of $29.65. The stock has a market capitalization of $927.20 million, a P/E ratio of -9.66 and a beta of 1.64. The company has a current ratio of 3.58, a quick ratio of 3.07 and a debt-to-equity ratio of 4.54.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The firm had revenue of $247.22 million for the quarter, compared to analysts’ expectations of $240.41 million. During the same period last year, the firm earned ($0.66) earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, equities analysts anticipate that Tandem Diabetes Care will post -0.79 earnings per share for the current year.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.